Investment Rating - The report assigns a "Buy" rating with a target price of HKD 28.35 per share, indicating a potential upside of 26% from the current price of HKD 22.50 [5][15]. Core Insights - The company is a leader in the domestic neurovascular and peripheral vascular interventional medical device sector, demonstrating high research and development efficiency with a diverse product line of 73 items, of which 51 are commercialized in China [4][7]. - The company has achieved significant international expansion, with revenue from international markets reaching RMB 15.7 million in the first half of 2025, a year-on-year increase of 36.9% [3][9]. - The company reported a total operating revenue of RMB 482 million for the first half of 2025, representing a year-on-year growth of 31.69%, driven by strong sales in neurovascular and peripheral vascular interventional devices [4][12]. Summary by Sections Investment Highlights - The company has a robust R&D platform that has successfully launched several innovative products, including the Qilin blood flow guiding device and OCT-guided peripheral vascular plaque directional cutting guiding catheter series [4][7]. - The company is actively expanding its international presence, with 22 products commercialized in 27 countries and entering 7 of the top 10 global markets [3][9]. - The company’s revenue growth is supported by the strong performance of its neurovascular and peripheral vascular interventional devices, with neurovascular product sales reaching RMB 304 million, accounting for 63.3% of total revenue [4][12]. Financial Projections - Revenue projections for 2025-2027 are RMB 1.056 billion, RMB 1.377 billion, and RMB 1.797 billion, respectively, with net profits expected to be RMB 223 million, RMB 309 million, and RMB 389 million [5][15]. - The company’s net profit margin is projected to improve significantly, with a forecasted net profit growth of 122.5% in 2025 and 38.6% in 2026 [6][15]. Market Position - The company is well-positioned in the market due to its competitive advantages in domestic substitution and continuous investment in R&D [5][15]. - The optimization of centralized procurement policies by the healthcare authority is expected to further enhance the company's future performance [4][12].

Core Viewpoint - The demand for cerebrovascular interventional devices in China is increasing due to the rising incidence of cerebrovascular diseases, which are among the top three causes of death in the country, with stroke being the leading cause [1][10]. Industry Definition and Classification - Cerebrovascular diseases are conditions affecting blood vessels in the brain, primarily including ischemic and hemorrhagic strokes. Cerebrovascular interventional surgery involves minimally invasive techniques for diagnosing and treating these conditions [2]. - Cerebrovascular interventional devices include medical consumables required for these surgeries, such as embolization coils, thrombectomy stents, and aspiration catheters [2]. Industry Characteristics - The cerebrovascular interventional device industry is characterized by high technical barriers, continuous technological innovation, and favorable industry policies [4]. Current Industry Status Global Market - The global market for cerebrovascular interventional devices is projected to reach USD 3.292 billion in 2024, with North America accounting for 43.04% of the market, Europe 26.56%, and Asia-Pacific 25.27%. The market is expected to grow to USD 3.974 billion by 2025 [7]. Chinese Market - In China, the market for cerebrovascular interventional devices is expected to reach CNY 3.504 billion in 2024, with specific segments such as intracranial thrombectomy stents at CNY 1.584 billion and aspiration catheters at CNY 0.272 billion. By 2025, the market is projected to grow to CNY 4.879 billion [10][13]. Industry Supply Chain - The upstream of the cerebrovascular interventional device industry consists of raw material suppliers, including tubing and alloy materials. The midstream includes manufacturers like Medtronic and Johnson & Johnson, while the downstream consists of distribution channels and end customers, primarily medical institutions [15].

Core Viewpoint - The demand for neurointerventional medical devices in China is increasing due to the rising incidence of cerebrovascular diseases, with stroke being the leading cause of death among Chinese residents. The market for neurointerventional consumables is projected to grow significantly in the coming years [1][5]. Industry Definition and Classification - Neurointerventional devices are medical consumables required for neurointerventional surgeries, primarily used to diagnose and treat cerebrovascular diseases through minimally invasive techniques [2][3]. Industry Development Status - The global market for neurointerventional consumables is expected to reach $3.292 billion in 2024, with North America holding a 43.04% market share. The Chinese market for these consumables is projected to grow from 3.504 billion yuan in 2024 to 4.879 billion yuan in 2025 [5][6]. Industry Chain - The upstream of the neurointerventional device industry consists of raw material suppliers, while the midstream includes manufacturers like Medtronic and Johnson & Johnson. The downstream consists of medical institutions that utilize these devices [7]. Industry Development History - The neurointerventional device industry in China has evolved through three stages: the embryonic stage (1980-1999), the initiation stage (2000-2010), and the rapid development stage (2011-present) [8]. Competitive Landscape - The market is primarily dominated by multinational companies such as Medtronic and Johnson & Johnson, while domestic companies like Guichuang Tongqiao and Micron Brain Science are gaining ground through competitive pricing and localized channels [9][10]. Key Enterprises - The leading companies in the Chinese neurointerventional market include Medtronic, Stryker, and Johnson & Johnson, with a significant presence of domestic players like Guichuang Tongqiao and Micron Brain Science [10][11]. Technological Breakthroughs - Domestic companies are achieving technological advancements in core products, allowing them to compete more effectively with international standards while benefiting from cost advantages [12]. Application Scenario Expansion - The application of new technologies such as AI-assisted navigation systems and biodegradable materials is expected to enhance the efficiency and scope of neurointerventional procedures, supported by favorable government policies [13].

– 1 – 歸創通橋醫療科技股份有限公司 公司章程 2025年12月 | 第一章 | 總則 | 3 | | --- | --- | --- | | 第二章 | 經營宗旨及範圍 | 5 | | 第三章 | 股份和註冊資本 | 6 | | 第四章 | 減資和購回股份 | 14 | | 第五章 | 購買公司股份的財務資助 | 16 | | 第六章 | 股票和股東名冊 | 17 | | 第七章 | 股東的權利和義務 | 22 | | 第八章 | 股東大會 | 26 | | 第九章 | 董事會 | 36 | | 第十章 | 董事會秘書 | 43 | | 第十一章 | 總經理 | 44 | | 第十二章 | 監事會 | 45 | | 第十三章 | 公司董事、監事、高級管理人員的資格和義務 | 47 | | 第十四章 | 財務會計制度與利潤分配 | 54 | | 第十五章 | 會計師事務所的聘任 | 57 | | 第十六章 | 公司的合併、分立、解散和清算 | 60 | | 第十七章 | 公司解散和清算 | 62 | | 第十八章 | 公司章程的修訂程序 | 65 | | 第十九章 | 通知和公告 | 65 | | 第二十 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Zylox-Tonbridge Medical Technology Co., Ltd. 歸創通橋醫療科技股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 註：具體以工商登記機關核准結果為準。 （股份代號：2190） 修訂公司章程 茲提述本公司日期為2025年8月19日及2025年10月24日的公告，以及本公司日期 為2025年10月8日的通函（「通函」），內容有關（其中包括）授權（「授權」）董事會 及╱或管理委員會辦理股份激勵計劃相關事宜。除另有界定外，所用詞彙與通 函所披露者具有相同涵義。本公告乃由本公司根據上市規則第13.51(1)條作出。 鑒於根據2025年股份激勵計劃授出的獎勵所涉及的1,395萬股H股已於2025年11 月7日發行及上市流通，本公司的註冊資本已由人民幣330,182,001元變更為人民 幣344,132,001元，總股本已由33 ...

证券日报网讯12月8日，建发致新（301584）在互动平台回答投资者提问时表示，公司目前供应商较为 多元化，主要供应商/生产企业包括但不限于中国的微创医疗、迈瑞医疗（300760）、归创通桥、赛诺 医疗、春立医疗，美国的美敦力、爱尔康、波士顿科学、史赛克，法国的思塔高、梅里埃等。 ...

Core Viewpoint - The article discusses the revenue breakdown and pipeline progress of leading cardiovascular device companies for Q3 2025, highlighting growth trends and market dynamics in the cardiovascular sector [11][15][21][27][33][38]. Market Review - The CITIC Medical Index decreased by 0.73%, underperforming the CSI 300 Index by 2.00 percentage points, ranking 22nd among 30 primary industries [7]. - Top-performing stocks included Haiwang Biological, Ruikang Medicine, and Guangdong Wannianqing, while the worst performers were ST Jingfeng and Kangzhi Pharmaceutical [7]. Overall Viewpoint and Investment Themes - **Innovative Drugs**: The domestic innovative drug industry is transitioning from quantity to quality, focusing on differentiated and internationalized pipelines, with a recommendation to pay attention to products that can ultimately generate profits by 2025 [9]. - **Medical Devices**: 1. The bidding volume for imaging equipment has significantly rebounded this year, with ongoing updates in equipment and supportive policies for home medical devices [9]. 2. The domestic market is seeing a notable increase in market share for leading domestic manufacturers due to the implementation of centralized procurement [9]. 3. The orthopedic sector is recovering well post-collection, with new innovations driving incremental revenue [9]. - **Innovation Chain (CXO + Life Science Services)**: There is an expected recovery in overseas investment and a potential bottoming out of domestic investment, indicating a new wave of innovation in the sector [9]. - **Pharmaceutical Industry**: The specialty API sector is anticipated to see cost improvements, leading to a new growth cycle [10]. Company-Specific Insights - **Abbott**: In Q3 2025, Abbott's cardiovascular revenue reached $3.137 billion, with a year-on-year growth of 12.5%. Key growth drivers included heart rhythm management and structural heart disease segments [15]. - **Medtronic**: Medtronic's cardiovascular revenue was $3.436 billion in Q3 2025, growing by 9.3%, with significant contributions from heart rhythm and heart failure segments [21]. - **Boston Scientific**: The company reported cardiovascular revenue of $3.343 billion, a 22.4% increase, driven by the growth of the Watchman and electrophysiology segments [27]. - **Johnson & Johnson**: The cardiovascular segment generated $2.213 billion in Q3 2025, with a 12.6% growth, supported by the acquisition of Shockwave and strong performance in electrophysiology [33]. - **Edwards Lifesciences**: The company achieved cardiovascular revenue of $1.55 billion, a 14.7% increase, with strong growth in transcatheter aortic valve replacement (TAVR) and mitral valve therapies [38]. Pipeline Developments - **Abbott**: The company is advancing its pipeline with new products in heart rhythm management and structural heart disease, including the AVEIR leadless pacemaker and Tendyne transcatheter mitral valve replacement system [16]. - **Medtronic**: The company is focusing on expanding its TAVR system and has received FDA approvals for several new products in the electrophysiology space [22]. - **Boston Scientific**: The company is enhancing its electrophysiology portfolio with the FARAPULSE PFA system, which has received FDA approval for expanded indications [28]. - **Johnson & Johnson**: The company is leveraging its acquisitions to enhance its product offerings in electrophysiology and heart failure management [34]. - **Edwards Lifesciences**: The company is expanding its TAVR and mitral valve product lines, with recent FDA approvals for new therapies [39].

Summary of Key Points Core Viewpoint - The latest shareholder equity disclosure for Guichuang Tongqiao-B (02190) and Huaxin Cement (06655) was conducted on December 5, 2025, revealing changes in shareholdings among various institutional investors [1]. Group 1: Guichuang Tongqiao-B (02190) - Zhuhai Tongqiao Investment reduced its holdings from 90.39 million shares to 88.39 million shares, maintaining a holding percentage of 26.28% [2]. - Zhuhai Guichuang Investment also decreased its holdings from 90.39 million shares to 88.39 million shares, with a holding percentage of 26.28% [2]. - Hangzhou Fujiang Investment's holdings decreased from 90.39 million shares to 88.39 million shares, retaining a holding percentage of 26.28% [2]. - Hangzhou Guichuang Enterprise's holdings were similarly reduced from 90.39 million shares to 88.39 million shares, with a holding percentage of 26.28% [2]. - Hangzhou Yuyi Huiqi's holdings decreased from 90.39 million shares to 88.39 million shares, maintaining a holding percentage of 26.28% [2]. - Wei Na's holdings also saw a reduction from 90.39 million shares to 88.39 million shares, with a holding percentage of 26.28% [2]. - Zhao Zhong's holdings decreased from 90.39 million shares to 88.39 million shares, maintaining a holding percentage of 26.28% [2]. Group 2: Huaxin Cement (06655) - Li Yeqing increased holdings from 1.13 million shares to 1.14 million shares, maintaining a holding percentage of 0.15% [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 歸創通橋醫療科技股份有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 322,400,744 | RMB | | 1 RMB | | 322,400,744 | | 增加 / 減少 (-) | | | 13,950,000 | | | RMB | | 13,950,000 | | 本月底結存 | | | 336,350,744 | RMB | | 1 RMB | | 336,350,744 | | 2. 股份 ...

Industry Investment Rating - The steel industry maintains an "overweight" rating [49] - The real estate industry maintains an "overweight" rating [57] - The insurance industry maintains an "overweight" rating [86] Core Viewpoints - Global risk preferences have significantly declined, leading to asset price fluctuations and panic selling. However, China's capital market is expected to recover in valuation and experience significant development, with A/H shares, industrial commodities recommended for tactical overweight, and US dollars for tactical underweight [20][21] - The Fed's expected interest rate cut in December has risen significantly, and the market is highly concerned about the Fed's monetary policy. The Chinese economy is expected to gradually stabilize, and the policies of various industries will promote the improvement of industry fundamentals [8][15] - The technology theme is expected to return to the main line, and themes such as commercial space, AI applications, robots, and domestic demand consumption are worthy of attention [29] Summary by Directory Macro Reports - **Global Asset Performance**: From November 24 - 28, 2025, major global stock markets rose, commodities generally increased, the 10 - year US Treasury yield remained unchanged, the US dollar index fell, and the RMB appreciated against the US dollar [5] - **US Economy**: Manufacturing new orders increased, housing price growth slowed, and consumer growth also slowed [6] - **European Economy**: Business confidence in the eurozone stabilized [7] - **Overseas Policies**: The Fed's expected interest rate cut in December rose to 80%, the ECB President said the current interest rate was appropriate, the UK's budget faced a "technical leak", Japan's bond - issuing plan tilted towards short - term bonds, and the BOJ's December interest rate hike expectation did not increase [8][9][10] - **China's Economy**: Consumption, investment, and production showed structural differentiation. The manufacturing PMI marginally rebounded due to improved external demand, and the construction industry's business activity index also increased marginally, but the service industry's declined [13][15] Asset Allocation Report - **A/H Shares**: Tactical overweight is maintained due to multiple factors supporting China's equity performance, such as the release of micro - trading risks and the approaching policy window [20] - **Treasury Bonds**: Tactical standard allocation is maintained because of the imbalance between financing demand and credit supply, and the central bank may take action to maintain market liquidity [20] - **Industrial Commodities**: Tactical overweight is maintained as industrial metals like copper may face supply - demand imbalances, with strong demand and increasing development costs [21] - **US Dollars**: Tactical underweight is maintained as the Fed's policy adjustment and the marginal convergence of the US economy reduce the dollar's allocation value [21] Strategy Reports - **Asset Overview**: Global risk preferences recovered, stocks and commodities rose, silver and copper prices hit record highs, and the dollar index weakened. A - shares and other major global stock markets generally rebounded, and the bond market showed a pattern of a bearish steepening in China and a bullish steepening in the US [23][24][25] - **Theme Analysis**: The trading heat of hot themes was stable, the technology theme returned, and funds flowed into AI and communication. Themes such as commercial space, AI applications, robots, and domestic demand consumption are recommended [29] Overseas Strategy Reports - **Fund Flows**: North - bound funds may have a small net inflow, and south - bound funds' inflow into e - commerce and retail reached a new high since October. Overseas funds showed different flow trends in different markets [36][37] - **Policy Tracking**: Domestic policies covered macro, industrial, and local aspects, and overseas policies included diplomatic, economic, and interest - rate - related policies [39][40][43] Industry Reports - **Steel**: Demand is expected to stabilize, supply is expected to contract, and the industry's fundamentals are expected to gradually recover. Companies with product and cost advantages are recommended [45][48][49] - **Utilities**: The proportion of long - term contract electricity in 2026 is expected to decrease, electricity prices may have limited declines, and the industry's valuation is expected to improve [52] - **Real Estate**: The transaction volume in large and medium - sized cities rebounded, and the spot - housing sales are beneficial to the industry's healthy development [57][58] - **Food and Beverage**: CPI data has boosted the sector's expectations. Different sub - sectors such as liquor, beverages, and snacks have corresponding investment recommendations [62] - **Robotics**: Overseas and domestic companies have made progress in the field of humanoid robots, and investment in this field is active. Core component suppliers and整机 manufacturers are recommended [67][68][69] - **Machinery**: The weekly operating load rate of industrial gases increased, and important projects such as the second - phase of the Huanneng Jintan salt - cavern compressed - air energy - storage project advanced. Related companies are recommended [73][74][75] - **Insurance**: In October 2025, the growth rate of life and property insurance premiums declined marginally. The industry is optimistic about the growth of the life insurance's new business value (NBV) in the 2026 opening season and the continuous improvement of the property insurance's combined ratio (COR) [83][84][85] - **Agriculture**: Corn prices rose, the pet food market showed different trends at home and abroad, and the pig - breeding industry needs to pay attention to the epidemic and demand. Related companies in different sub - sectors are recommended [88][89][90] - **Textile and Apparel**: The US clothing retail industry showed growth, and the overseas K - shaped consumption trend continued. Export - manufacturing and brand - end companies are recommended [93][94][95]